Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer
This paper documents the discovery of a new driver mutation in bladder cancer, present in ~10% of the studied cancer patients. The mutation is a deletion of exons 8 and 9 in the aryl hydrocarbon receptor (AHR) gene. SORT-seq analysis confirmed that a transformed, tumor-related expression profile arose due to mutated AHR in mouse bladder organoids.
- DOI: 10.1038/s41598-022-14256-0
- PMID: 35710704